Duke breast oncologist and professor Kimberly Blackwell, MD, is slated to address a session on “Predictive Biomarkers in ImmuoOncology” at the PMWC 2018 (Precision Medicine World Conference), to be held January 22 to 24 at the Computer History Museum in Mountain View, California.
Blackwell, who’s also a professor of medicine and assistant professor of radiation oncology, is the featured speaker at the session and Ann Kapoun, PhD, associate director of Biomarker R&D in Clinical Pharmacology & Experimental Medicine at ALZA/Johnson & Johnson, is the session chair.
The session will review the challenges and opportunities of predictive and prognostic biomarker development in immune-oncology to guide safe and effective therapy use. As immunotherapies become a backbone of cancer treatment, researchers say biomarker assays will be critical to optimize the use of immunotherapies as a single agent or in combinations.
One of the nation’s leading breast cancer researchers, she has played a major role in developing therapies that represent revolutionary non-chemotherapy based approaches for treating breast cancer. Her work led to the approval of the first biosimilar treatment for cancer in the U.S.
Her current research interests include triple negative breast cancer and cancer that has spread to the brain, and she has served as the principal investigator or co-principal investigator for more than 50 clinical trials.
A full breakdown of session themes at PMWC 2018 and the program schedule can be accessed on the conference website.
To take advantage of an early bird registration discount (10 percent off) for the conference, register here through 9.29.17.